Pennington Biomedical begins recruitment for study of diabetes
BATON ROUGE - Pennington Biomedical Research Center announced recently that it is recruiting volunteers for a new clinical study that will compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes.
The project is called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study.
The National Institutes of Health (NIH)-funded study will compare drug effects on glucose levels, adverse effects, diabetes complications and quality of life over an average of nearly five years.
GRADE aims to enroll about 5,000 patients from across the United States, with 150 patients coming from Baton Rouge and the surrounding area.
Investigators at Pennington Biomedical and 36 other study sites are seeking people diagnosed with type 2 diabetes within the last five years. They must be at least 30 years of age and may be on metformin, but not on any other diabetes medication.
During the study, all participants will take metformin, along with a second medication randomly assigned from among four classes of medications, all approved for use with metformin by the U.S. Food and Drug Administration.
Participants will have their diabetes medications managed free of charge through the study, including at least four medical visits per year, but will receive other health care through their own providers.
Learn more about the study at https://grade.bsc.gwu.edu. To determine eligibility, call 225-763-3000 or visit www.pbrc.edu/GRADE.